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Tissue-resident macrophages (MVs) are phagocytic cells actively
contributing to the maintenance of homeostasis and immune surveil-
lance and the resolution of inﬂammation.1,2 Their origin varies with
their home tissue and is controlled by speciﬁc transcription factor
expression.3 In recent years, it has become clear that the physiological
environment of tissue-resident MVs is crucial to their function4–8
and, hence, in vivo study is essential for physiological relevance.
Important progress has been made to genetically target MVs in vivo.9
Particularly, the introduction of alternative envelopes10 andMV-spe-
ciﬁc synthetic promoters11 have been proposed to alter the precision
of MV lineage targeting. Here, we employ a commonly used broadly
tropic vesicular stomatitis virus envelop glycoprotein (VSV-G) pseu-
dotyped lentivirus vector with transgenes driven by spleen focus-
forming virus (SFFV) promoter and show a natural propensity for
peritoneal MV (pMV) infection after intraperitoneal (i.p.) injection.
Lentiviral vectors12 have proven to be excellent tools to modify gene
expression in both human and murine cells.13–17 In this context, we
describe an optimized protocol allowing predominant tissue-resident
peritoneal MV gene expression in vivo, resulting in successful genetic
modiﬁcation of peritoneal MVs in their physiological environment.18
Being highly ﬂexible, this technique can be used to either overexpress
or downregulate gene expression in peritoneal MVs both at steady
state and during inﬂammation.Molecular Therapy: Methods &
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Reagents
 DMEM (1) + 4.5 g/L D-glucose, 400 mM L-glutamine (Thermo
Fisher Scientiﬁc)
 RPMI 1640 medium (1) + 400 mM L-glutamine (Thermo Fisher
Scientiﬁc)
 AimV medium (Thermo Fisher Scientiﬁc)
 Fetal calf serum (FCS) (heat-inactivated for 30 min at 56C)
 Penicillin/streptomycin (100, 10,000 U/mL) (Life Technologies,
cat#15140122)
 Sterile Dulbecco’s PBS (DPBS) (1) Mg++- and Ca2+-free
(Gibco, cat#14190144)
 0.05% Trypsin-EDTA (1) (Trypsin 500mg/L or 0.02mM)
(Gibco, cat#25300054)
 20% (w/v) Sucrose
 Sodium hypochlorite (bleach, 2,000 ppm)Clinical Development Vol. 16 March 2020 ª 2019 The Authors. 21
the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Molecular Therapy: Methods & Clinical Development Hydrex surgical scrub, chlorhexidine gluconate 4% w/v skin
cleanser (Ecolab, cat#3037170)
 4% (w/v) Paraformaldehyde (PFA)
 Effectene transfection reagent (QIAGEN, cat#301425)
 LIVE/DEAD ﬁxable near-IR dead cell stain kit (Thermo Fisher
Scientiﬁc, cat#L34975)
 Sodium thioglycolate (96.5%) (Sigma-Aldrich, cat#T0632)
 Collagenase type IV (Sigma-Aldrich, cat#C5138)
 DNase I (Sigma-Aldrich, cat#11284932001)
 Hyaluronidase (Sigma-Aldrich, cat# H3506)
 Saponin (Sigma-Aldrich, cat# S4521)
Equipment
 CO2 incubator
 Cat II biology safety cabinet
 Cell culture ﬂask 175cm2, 550 mL (CellStar, T175 ﬂask)
 Sterile VWR disposable transfer pipets 23.0 mL, 30 cm (VWR)
 Conical centrifuge tubes (15 mL and 50 mL)
 Microcapillary pipettes (volume range 0.5–1,000 mL)
 Syringes (50 mL and 10 mL)
 0.5 mL U-100 insulin syringe with needle, 0.33 mm, 29G 
12.7 mm (BD MicroFine+)
 Sterile 23G 1” 0.6 mm  25 mm nr16 needles (BD
Microlance)
 0.45 mm Sterile millex GP ﬁlter (Millipore, cat#SLHP033RS)
 40 mm Strainer (Thermo Fisher Scientiﬁc, cat# 22363547)
 Sterile 24-well cell culture plate
 U-bottom 96-well cell culture plate
 Centrifuge tubes, conical bottom tubes 25  89 mm (Beckman
Coulter, cat#358126)
 Centrifuges (ultracentrifuge and TC centrifuge)
 1.5 mL O-ringed screw tubes (or cryotubes)
 Forceps
 Surgical scissors
 Petri dish
 Needle-proof container
 Flow cytometer
 Ultracentrifuge (Beckman Coulter)
 Fluorescent tissue culture microscope, e.g., EVOS FL (Thermo
Fisher Scientiﬁc)
 Mice (mice described in this protocol were C57BL/6 females, aged
8–12 weeks and obtained from Charles River)
Reagent Setup
Plasmids
The pCMV-DR8.91 packaging plasmid encodes Gag-Pol HIV
proteins driven by the cytomegalovirus (CMV) promoter.19
pMD2.G encodes the VSV-G expressing plasmid driven by CMV
promoter.20
The EGFP expressing vector was pHR’SIN-cPPT-SEW plasmid.
EGFP is downstream of the SFFV promoter and upstream of the
Woodchuck hepatitis virus enhancer.18 All plasmids are ampicillin
resistant in bacteria.22 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchCells
HEK293T cells were maintained in DMEM supplemented with 10%
FCS, 100 U/mL penicillin, and 10 mg/mL streptomycin (complete
DMEM [cDMEM]). Jurkat cells were maintained in RPMI 1640 sup-
plemented with 10% FCS, 100 U/mL penicillin, and 10 mg/mL strep-
tomycin (cRPMI). Both cell lines were kept at 5% CO2 and 37C. It is
crucial to ensure the low passage and healthy condition of both cell
lines for optimal results. Speciﬁcally, poor viability of HEK293T cells
will result in low lentiviral yield. Both cell lines should be defrosted at
least 1 week prior to usage to recover from freezing. Cells should be
mycoplasma free.
Mice
All animal work was conducted in accordance with Institutional
and UK Home Ofﬁce guidelines. Users should make sure their own
animal licence authorize work with lentivirus in mice.
Flow Cytometry Buffer
Fluorescence-activated cell sorting (FACS) buffer is used during ﬂow
cytometry staining, but can also be used for lavage of the peritoneal
cavity (as an alternative to 5 mM EDTA in PBS), and contains 4%
heat-inactivated and 0.22 mm ﬁltered FCS and 1 mM sterile EDTA
(Affymetrix) in sterile PBS. Perm buffer for intracellular staining con-
tains additional 0.5% w/v saponin.
Blocking Buffer
Blocking buffer contains 10% (v/v) rat serum, 4 mg/mL 2.4G2 anti-
body (made in house), and 1 mM EDTA in sterile PBS. 2.4G2 anti-
body minimizes nonspeciﬁc binding of antibodies by blocking
FcgR receptors II and III and thus is a highly recommended compo-
nent of the blocking buffer for staining Fc receptor expressing cells.
20% Sucrose
Sucrose (20%w/v) was dissolved in Milli-Q water and sterile ﬁltered
using 0.22 mM ﬁlters. Aliquots can be stored at 4C.
Thioglycolate
Thioglycolate was obtained from Sigma-Aldrich, and 4% stock solu-
tion was prepared in water. The solution was autoclaved and kept
frozen prior to use. For the experiment, 0.1 mL of 4% thioglycolate
was injected i.p.
Equipment Setup
The safety and good working condition of the ultracentrifuge must be
conﬁrmed before use. A detailed description of the ultracentrifuge
setup is provided in 2.2. Lentivirus Puriﬁcation. We recommend
decontaminating buckets and lids after each centrifugation
with 70% (v/v) ethanol. Avoid using cleaning detergents that can
harm anodized aluminum.
PROCEDURE
The protocol below is optimized for transfection of a T175 ﬂask of
HEK293T cells, which corresponds to 1mL (or 1.5 mL if using Option
B in 2.1.2 Lentivirus Collection) of ﬁnal lentivirus preparation. The2020
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Figure 1. Time Frame Summarizing the Workload
from Lentivirus Production to In Vivo Testing
The protocol can be divided in 3 major steps: (1) lentivirus
production, which takes 2 days; (2) lentivirus in vitro
testing, which takes 3 days; and (3) in vivo gene modifi-
cation, which can take up to 7 days. Most of the time
indicated here is waiting time (orange), and the actual
active manipulation time is indicated in blue.
www.moleculartherapy.orgtime frame and overview of the complete protocol is shown in Fig-
ure 1. Lentivirus-mediated modiﬁcation of cells is widely used in
studies, and this protocol has been optimized for effective infection
of mouse tissue-resident peritoneal MVs. However, pure lentiviral
preparation can also be utilized for in vitro infections. For the purpose
of this paper, we used EGFP as the main readout.
1. HEK293T Cell Transfection (Day 1)
1.1. HEK293T Cell Defrosting and Preparation (Day –6)
HEK293T cells should be stored frozen in liquid nitrogen for long-
term storage. We recommend defrosting cells 1 week prior to the start
of lentivirus production. It is essential that cells are healthy and in
good numbers to achieve the best results from the below protocol.
HEK293T cells require a passage every 2–3 days if grown in optimal
conditions (up to 70%–80% conﬂuency). Ensure your cells are healthy
before starting the protocol.
1.2. HEK293T Cell Seeding for Transfection (Day 0)
One day before transfection, adherent HEK293T cells are freshly
seeded in appropriate culture volumes. The cells are gently washed
with sterile room temperature PBS (add PBS to the wall of the
ﬂask, avoiding disruption of the cell monolayer). Remove PBS
and add 7–10 mL of trypsin (for a T175 ﬂask) to the cells. The cells
should fully detach during a 5-min incubation at 37C in a 5% CO2
incubator. Inactivate trypsin by adding an equal volume of
cDMEM and collect the cells and harvest them by centrifugation
for 5 min at 350 g at room temperature. Carefully remove the su-
pernatant, resuspend the cells in cDMEM, and count. Seed
10–11  106 of viable HEK293T cells per T175 ﬂask in 20 mL of
cDMEM. Maintain the cells at 37C in a 5% CO2 incubator for
1 day before transfection.
1.3. Transfection Using an Effectene Kit (Day 1)
Change the medium of the HEK293T cell monolayer to fresh cDMEM
(15mL), taking care not to disturb themonolayer. Prepare the transfec-
tion mix as recommended by the manufacturer by adding lentiviral
components: 2 mg lentiviral plasmid encoding your gene of interest,
1.5 mg pCMVD8.91, and 1 mg pCMVMD2G. Make up the volume toMolecular Therapy: Methods &600 mL with buffer EC, included in Effectene
kit. Add 36 mL of enhancer and mix gently with
a 1 mL pipette. We recommend mixing by suck-
ing up part of the liquid and putting it back drop
by drop. Repeat several times and incubate atroom temperature for 5min. Add 120mL of Effectene andmix as above,
pipetting up and down approximately 20 times. Incubate at room tem-
perature for 10 min. Top up the volume with 5.2 mL of cDMEM and
mix as above, this time using a 5 mL stripette. Using a disposable trans-
fer pipet, collect the whole volume (6 mL) and add drop-wise directly
onto the HEK293T cell monolayer. Rock the plate gently side to side
to allow equal distribution of the plasmid. Keep the cells for 48 h in a
5%CO2 incubator at 37C.Taking caution not to disturb the cellmono-
layer, check for EGFP (or if needed, the other readout marker used)
expression in the transfected cells 24–48 h post transfection. For
EGFPdetection, we used the EVOScell imaging system (ThermoFisher
Scientiﬁc). Strong EGFP signal can be seen 48 h post HEK293T cell
transfection (Figure 2A). EGFP signal intensity can vary depending
on the transfer vector content.
1.4. Safety Considerations
Lentivirus is a category II pathogen, and speciﬁc safety procedures
should be followed when handling infected animals, cells, and tissues
(for details, see Box 1). HEK293T cells transfected in this protocol are
considered infectious from the point of transfection, and safety pre-
cautions should be implemented when handling these cells. Any
waste products should be considered as category II contaminated
and disposed of according to institutional regulations.
2. Lentivirus Collection and Purification (Day 3)
2.1. Lentivirus Collection
2.1.1. First Collection. 48 h post transfection, some detached
HEK293T cells can be observed in the ﬂask. Gently collect the me-
dium from the transfected HEK293T cells without disturbing the
cell monolayer and transfer to a 50 mL falcon tube. If you wish to pro-
ceed with the optional second collection step [see 2.1.2 Second Collec-
tion (Optional)], replace the medium with 21 mL of fresh cDMEM
without disturbing the cell monolayer and place the ﬂask back in
the incubator for an additional 24 h. If not proceeding with the
optional second collection step, discard the cells and ﬂask following
appropriate category II regulations. Continue with the lentivirus pu-
riﬁcation (2.2 Lentivirus Puriﬁcation).Clinical Development Vol. 16 March 2020 23
A Brightfield GFP Merged
400μm
B
20% sucrose
Medium containing
 lentiviral particles
Figure 2. Lentivirus Production from HEK293T Cells
and Purification
(A) Representative immunofluorescence pictures of
HEK293T cells 48 h after transfection were taken using an
EVOS microscope. EGFP is used as a reporter and is
inserted in the expression plasmid pSEW. (B) Photograph
showing the ultracentrifuge conical tube containing both
the layer of 20% sucrose (bottom, clear layer) and me-
dium collected from transfected HEK293T cells (top, red
layer).
Molecular Therapy: Methods & Clinical Development2.1.2. Second Collection (Optional). 12–24 h post ﬁrst collection,
repeat the above step, but, this time, discard the cells and ﬂask
following appropriate category II regulations. Continue with the
lentivirus puriﬁcation (2.2 Lentivirus Puriﬁcation). It is important
to remember that the second lentivirus collection must be titerd sepa-
rately to the ﬁrst collection as preparations will have slightly different
titer.
2.2. Lentivirus Purification
Pass the collected medium through a 0.45 mm ﬁlter into a fresh 50 mL
falcon using a 50 mL syringe. It is essential not to use smaller ﬁlters
(e.g., 0.22 mm) as this will result in the loss of lentivirus particles.
Lentivirus particles might bind to cellulose ester membranes and,
for better recovery, it is recommended to use low protein-binding pol-
yether sulfone or polyvinylidene ﬂuoride ﬁlters.21 In conical bottom
30 mL ultracentifuge tubes, ﬁrst lay 3 mL of 20% sucrose and very
carefully overlay the 26 mL of the ﬁltered medium. Two separate
layers should be visible (Figure 2B). If the volume of the ﬁltered me-
dium is less than 26 mL, top it up with fresh cDMEM. This will not
affect the ﬁnal lentiviral stock and is essential to avoid collapsing
the ultracentrifuge tube during the spin.
We recommend that any staff using the ultracentrifuge receive appro-
priate training prior to usage to avoid injuries. Once the rotor is
securely inserted, close the lid, start the vacuum, and spin the samples
at 26,000 rpm for 90 min at 4C. At the end of the run, carefully re-
move the rotor and apply class II lentivirus precaution again
(see Box 1). Pure lentivirus particles should pellet to the bottom of
the tube, but this pellet will not be visible to the naked eye. In one
smooth motion, tip out sucrose and medium into a bleach pot and,
keeping the tube inverted, place it upside down on paper tissue for
10 min. If any leftover medium accumulates on the tube walls, care-24 Molecular Therapy: Methods & Clinical Development Vol. 16 March 2020fully remove it with a small piece of tissue before
turning the tube the right way up. Gently resus-
pend the lentivirus pellet in 1 mL of AimV
medium using a 1,000 mL pipette. When per-
forming the optional second collection [see
2.1.2 Second Collection (Optional)], resuspend
the lentivirus pellet in 500 mL of AimVmedium
instead, to ensure comparable titers between the
collections. Leave at room temperature for
15 min. Gently mix the virus with the1,000 mL pipette before aliquoting into 1.5 mL cryotubes. We recom-
mend preparing aliquots of 100 mL, which is the optimal dose for i.p.
injection (see 4. In Vivo Lentivirus Infection of peritoneal MVs) plus
additional volume to account for pipetting error.We also recommend
freezing one vial with about 20 mL of lentivirus stock to be used for
titer validation.
3. Lentivirus Infectivity Validation (Days 4–7)
We observed very little variation between lentivirus titers of different
preparations when using the same plasmid. However, depending on
the plasmid constructs, the infectivity of the lentivirus can change.
Therefore, we recommend titration of every lentivirus production
and standardization of the injection volume before proceeding with
experiments.
An easy and reliable way to estimate virus infectivity is to use
healthy Jurkat T cells defrosted 1 week before infection. On the
day of the infectivity test, seed Jurkat T cells in 24-well plates at
2  105 cells/well in 200 mL of cRPMI1640. On ice, thaw the
lentivirus production vial containing 20 mL of the stock (see 2.2.
Lentivirus Puriﬁcation) and mix gently, pipetting up and down. Us-
ing serial dilution, infect Jurkat T cells with 0.25, 0.5, 1, 2.5, 5, and
10 mL of lentivirus stock. Keep non-infected Jurkat cells as negative
control. Gently rock the plate to assure equal distribution of the
virus. Incubate at 37C for 4 h, and then add cRPMI1640 to reach
a total volume of 400 mL per well. 3 days after infection, collect the
cells in 1.5 mL collection tubes and centrifuge the cells at 350 g at
4C for 5 min. Discard the supernatant and resuspend the pellet
with 2% paraformaldehyde. Leave it for 15 min in the dark.
Although EGFP is quite a stable protein, we recommend keeping
the samples protected from light from this point on. After ﬁxation,
centrifuge the cells at 350 g at 4C for 5 min and resuspend the
Box 1: Recommendation for the Safe Handling of Lentivirus
Lentiviruses are considered class II material and should be handled in accordance with local safety regulations. We recommend each lab to
have written standard operating procedures (SOPs) and risk assessment (RA). This is a non-exhaustive list of the precautions we have
implemented in our laboratory that may serve as an example, but it needs to be adapted to every local regulation.
 Work under a category II safety hood.
 Double glove when handling contaminated material, and remove the top glove when handling anything not contaminated.
 Special caution should be taken when using sharp objects and their use should be limited to a minimum, with the exception of insulin or
single-use safety needles.
 When possible, dedicate a separate incubator for lentivirus.
 Any item coming in contact with contaminated material should be bleached with at least a 2,000 ppm bleach solution for a least 4 h
inside the category II hood prior to disposal.
 In case of spillage, immediately cover the contaminated liquid with granulated bleach.
www.moleculartherapy.orgpellet in ﬂow cytometry buffer. Run the cells on a ﬂow cytometer
and analyze the percentage of infected cells as well at the mean ﬂuo-
rescent intensity (MFI) of the infected cells, as illustrated in Figures
3A–3C. Jurkat T cells are known to be easily infected by lentivirus,22
and 5 mL of lentivirus stock should be sufﬁcient to achieve close to
100% infection. Noticeably, the MFI increases with the lentivirus
dose (Figure 3C).
It is crucial to test the infectivity of control (empty vector or scram-
bled short hairpin RNA [shRNA]) and vector of interest (overexpres-
sion or targeted shRNA) in Jurkat T cells on the same day to assure
accuracy and optimal in vivo experiment.
4. In Vivo Lentivirus Infection of Tissue Resident peritoneal MVs
(Days 8–22)
All in vivo studies with lentivirus should be performed according
to local and national guidelines on the ethical use of animals in
research as well as adhering to all regulations associated with the
use of category II infectious materials. Animal welfare should
also be monitored in accordance with local regulations. Injections
and collection of samples should follow local authority rules
(see Box 1).
Here we describe an optimal working system we have implemented in
our laboratory to ensure both the safety of the worker and welfare of
the mice. This system may be modiﬁed to individual laboratory re-
quirements and local rules.
Prepare lentivirus-containing insulin needles (or single-use needles,
30G for animal welfare and to avoid ﬂuid loss in the needle) within
30 min of planned i.p. injections and store on ice in a lockable box un-
til the time of injection. Drawing the lentivirus up into the syringes
should be done in a category II biological safety cabinet considering
the safety issues (Box 1). The needle sheath should be placed back
on the needle using the one-hand scoop technique. Guide the needle
into the sheath using only one hand to hold the syringe and press the
sheath against a solid structure such as the inside wall of the safety
cabinet or the side of a tip box.MoleculSet up category II biological safety processes prior to injections: our
typical setup is shown in Figure 4. Before injections, loosen the sheath
of the insulin needle containing the 200 mL lentivirus solution. Manu-
ally restrain the mouse with abdomen facing up and head pointed
slightly down. Intraperitoneally inject the lentivirus into lower left
quadrant of the abdominal cavity, avoiding injection into any perito-
neal cavity organs. Still holding the mouse, ﬁll the syringe with 2,000
ppm bleach and safely dispose of it in the sharp safe box. Wipe the
injection site on the mouse abdomen with tissue soaked in chlorhex-
idine gluconate-based disinfectant (such as Hydrex surgical scrub)
before returning the animal to the cage. Keep the lentivirus-injected
mice in category II scantainers (isolated cages with high efﬁciency
air ﬁltration) for a minimum of 72 h after injection before returning
them to category I holding cages and monitor daily. We have never
recorded any wellbeing issues caused by lentivirus injection, but extra
precaution should be taken when testing this protocol for the ﬁrst
time.
5. Peritoneal Cell Collection from Infected Mice (Days 8–22)
Mice and associated tissue samples are considered category II infec-
tious until up to 72 h after injection. If peritoneal lavage is performed
during that time frame, sample collection should be carried out
following local category II safety guidelines (see Box 1). Samples are
ﬁxed with 2% PFA or lysed.
Euthanize mice by increasing the concentration of CO2 inhalation
and conﬁrm death by cervical dislocation or by following the local
animal license recommendation. If samples are collected within
72 h post lentivirus injection, the presence of cell-free lentivirus in
tissues is likely, and the following steps must be performed in a cate-
gory II biological safety cabinet in accordance with safety regula-
tions. Immediately spray the mouse abdomen with 70% isopropanol
and carefully cut the skin to expose the peritoneal cavity membrane.
Lavage the peritoneal cavity by briskly injecting 6 mL of ice-cold
FACS buffer using a 10 mL syringe and 23G needle. Gently roll
the mouse to allow the FACS buffer to wash over the peritoneal cav-
ity. Collect the peritoneal ﬂuid using the same syringe and needle,
but remove the needle before transferring the cells to 15 mL falconar Therapy: Methods & Clinical Development Vol. 16 March 2020 25
A B C Figure 3. Lentivirus Titer Validation
Representative flow cytometry analysis of Jurkat T cells
72 h after infection with lentivirus containing an EGFP+
plasmid. Percentage of EGFP+ (GFP+) cells (A), mean
fluorescence intensity (MFI) of GFP+ cells (B), and histo-
gram representation (C) clearly show the infection rate of
the different lentivirus doses.
Molecular Therapy: Methods & Clinical Developmenttubes. To maximize the recovery of the MVs, a second lavage could
be performed as described above. Store the peritoneal lavages on ice
until further processing. Dispose of animal carcasses according to
local animal guidelines.
6. Peritoneal Cell Staining and Analysis (Day 13)
The viability of the collected cells is expected to be between 98%–
100% when measured within 1 h of collection. The number of
collected cells can vary depending on mouse strain, treatment,
and lavage technique. As a rough indication, about 2.5  106 cells
usually can be isolated from naive 8–12-week-old C57BL/6 female
mice.
Count the collected peritoneal cells and ﬁx them in 2% PFA for
15 min on ice. Wash the cells with cold PBS and distribute them
in a V-bottom 96-well plate at 4  105 cells per well. Traditional
ﬂow cytometric staining protocol can be followed from that step on-
ward. For viability staining (LIVE/DEAD Fixable Near-IR Dead Cell
Stain Kit, Thermo Fisher Scientiﬁc), the manufacturer instructions
were strictly followed (1:1,000 dilution in PBS, staining for
30 min before ﬁxating with 4% PFA for 15 min). For cell surface
staining, centrifuge the plate at 350 g for 5 min at 4C and resus-
pend the pellet in 50 mL blocking buffer. For intracellular staining,
prepare the blocking buffer in perm buffer and leave it on ice for
15 min. Add an equal volume of antibody mix prepared in ﬂow cy-
tometry buffer or perm buffer to each well and keep on ice, pro-
tected from light, for 30 min. Unstained cells and isotype controls
should be included as required. Wash cells twice with ice-cold
PBS, centrifuging the plate at 350 g for 5 min at 4C between
each wash. Analyze samples on a ﬂow cytometer.
7. Enzymatic Digestion of Organs
For isolation of cells from the spleen, lungs, liver, and lymph
nodes, excise and mince the organs with scissors in 1 mL digestion
mix containing Hank’s balanced salt solution (HBSS) and
2 mg/mL collagenase type IV and 0.03 mg/ml DNase I (addition-
ally supplemented with 1.5 mg/mL of hyaluronidase for lung
digestion). Pass the cells through 40-mm strainers and centrifuge
for 5 minutes at 350 g at 4C. For lung, spleen, and liver samples,
lyse red blood cells using Ammonium-Chloride-Potassium (ACK)
lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM NA2EDTA,
pH 7.2) and pass the samples again through a 40-mm strainer.
Continue cell staining and analysis as described in 6. Peritoneal
Cell Staining and Analysis (Day 13).26 Molecular Therapy: Methods & Clinical Development Vol. 16 March8. Establishment of the Best Dose and Timing for Resident
peritoneal MV Lentivirus Infection In Vivo
Table S1 lists the antibodies and corresponding dilutions used in this
protocol to analyze different cell populations in the peritoneal cavity.
Gating strategies for peritoneal cavity cell populations can be found in
Figure S1.
To establish the optimal lentivirus dose for in vivo MV studies, we
ﬁrst injected 50, 100, 150, or 200 mL of lentivirus stock in a total vol-
ume of 200 mL of AimV medium i.p. and analyzed the infection efﬁ-
ciency 3 days post injection. Injection of 200 mL of AimV medium
served as negative control. peritoneal MVs can be easily distinguished
from other cells in the peritoneal cavity by their expression of speciﬁc
markers: CD11b+ F4/80+ and Tim4+ (Figure 5A). The best infection
efﬁciency of peritoneal MVs, as measured by EGFP expression, was
achieved using 100 mL of lentivirus preparation (Figures 5B and
5C). Injection of higher doses of lentivirus (150 mL and 200 mL) did
not improve the percentage of EGFP+ peritoneal MVs.
Besides using the best dose to obtain the optimal infection efﬁciency,
it is important to consider the best time to harvest the cells. Having
identiﬁed 100 mL as the optimal dose, we performed a time-depen-
dent experiment where the mice received 100 mL of lentivirus (in a to-
tal volume of 200 mL AimV), and peritoneal cells were harvested 4 h,
3 days, 7 days, and 14 days after injection. Based on the longevity of
the EGFP signal in infected resident peritoneal MVs (Figures 5D and
5E), we identiﬁed the optimal experimental time being between 3–
7 days post i.p. injection. Resident peritoneal MV infection can be
additionally conﬁrmed by staining the cells for HIV type 1 (HIV-1)
core antigen, composed of the 55, 39, 33, and 24 kDa proteins (pre-
cursor, intermediate products, and core protein) and analyzing the
cells using ImageStream (Figure 5F). The gating strategy of F4/80+
peritoneal MVs (excluding doublets and cells not in focus) is shown.
Clear populations of productively (EGFP+ F4/80+ core antigen+) and
unproductively (EGFP F4/80+ core antigen+) infected peritoneal
MVs can be distinguished. Unproductive infection results from a fail-
ure in lentivirus post cell-entry life-cycle steps, such as reverse tran-
scription or integration, and should be anticipated in cells, especially
in MVs and dendritic cells (DCs) that express lentivirus restriction
factors.23 All peritoneal cells exhibited high viability (single cells),
similar to control injected animals (Figure 6A).
It is interesting to note that resident peritoneal MVs can be further
divided into additional subpopulations, such as CD73+ and CD732020
1 2
3
4
5
Figure 4. Optimal Setup of the Cat II Hood and Material before In Vivo
Injection
Photograph illustrating the optimal organization of the workplace, for a right-handed
manipulator, before starting in vivo work. A left-handed manipulator will have to
invert the disposition of all items: (1) clean tissue; (2) insulin syringe loaded with
200 mL AimV medium containing lentivirus and a loose cap; (3) Petri dish containing
small pieces of tissue (right) and Hibiscrub (left) to disinfect the mouse after i.p.
injection; (4) 50 mL falcon containing 2,000 ppm bleach (right) to bleach the syringe
after injection and remaining Hibiscrub (left); (5) sharp safe box to dispose of the
insulin syringe after injection.
www.moleculartherapy.orgTim4+ peritoneal MVs (Figure 6B), and that these populations
appear to be differentially infected by lentivirus (Figure 6C). CD73
is given here as an example, and investigators interested in a partic-
ular resident peritoneal MV subpopulation should perform similar
experiments with the marker of their interest to validate the infection
efﬁciency of their cells of interest. Importantly, we demonstrate that
productive infection with lentivirus is limited to resident peritoneal
MVs in the peritoneal cavity, as evidenced by a lack of signiﬁcant
EGFP expression in MVs in mesenteric lymph nodes (mLNs),
lung, livers and spleen 7 days post lentivirus peritoneal challenge
(Figure 6D).
We next examined the effectiveness of this protocol under the inﬂam-
matory condition (Figures 6E and 6F). Inﬂammation was induced by
i.p. injection of 0.1 mL of 4% thioglycolate, a dose associated with an
inﬂux of inﬂammatory monocyte-derived recruited MVs coexisting
with recoverable resident peritoneal MVs. We demonstrated that
monocytic-like cells (Ly6Chi populations 1 and 2) exhibited minimal
evidence of infection. Additionally, our data show that the lentivirus
transduction susceptibility of resident MVs and monocytes (groups
3–5) corresponded to their phenotypic convergence on the recog-
nized phenotype of resident peritoneal MVs, which remained most
easily infected. Monocytic-like cells have previously been reported
to be refractory to productive lentivirus infection.24
One concern when using i.p lentivirus infection is the potential for
lentivirus-induced inﬂammation. Type I interferons (IFNs) are pro-
duced and released in response to viral infections. Therefore, we inves-
tigated the IFN response in the mouse peritoneal cavity after lentivirus
injection using ProcartaPlex mouse IFN-a/IFN-b 2-plex multiplex
immunoassay (Invitrogen) according to the manufacturer’s instruc-Molecultions. Both IFNs remained below a detectable level in all samples tested
at 4 h and 3, 7, and 14 days post injection, thus indicating a lack or very
low level of this cytokine release during lentivirus challenge in the peri-
toneal cavity (data not shown) in line with previous ﬁndings.25
Thorough analysis of most of the peritoneal cell populations after in-
jection of 100 mL lentivirus (in 200 mL total AimV volume) (Figure 7)
showed that only mild inﬂammation occurs, mainly 4 h after injection,
as indicated by the transient inﬂux of a relatively low number of neu-
trophils (Figures 7A, top graph, and S2). However, these neutrophils
did not seem to be productively infected, based on EGFP expression
analysis (Figures 7B and S3). B and T cell (CD19+ and CD3+, respec-
tively) percentages and absolute count do not vary over time or with
increased doses (Figure S2, top graphs) and they are not infected, as
determined by a lack of EGFP positivity. Mast cells, natural killer
(NK) cells, and eosinophils also remained EGFP (Figure 7B).
Interestingly, the resident peritoneal MV population (F4/80+ Tim4+)
is stable until day 7 after injection, but it experiences a major drop in
percentage (Figure 7A, middle graph) and number (data not shown)
between days 7 and 14. Interestingly, the infected cells persist at day
14 in EGFP transgenic mice, suggesting that the drop in resident peri-
toneal MV numbers is, at least in part, due to immune response to the
transgene (unpublished data). In contrast, the major histocompatibil-
ity complex (MHC) class II+ resident peritoneal MVs (MHC class II+
F4/80+ Tim4+) are also readily infected (up to 60% at day 3 after in-
jection, Figure 7A, lower graph), while their percentage of EGFP+ cells
also completely drops by day 14 (Figure 7A, lower graph). Other
bone-marrow derived peritoneal MVs/DCs (MHC class II+ MVs/
DCs), deﬁned as CD11b+ CD11c+ MHC class II+, seem to be only
minimally affected by the lentivirus in terms of number and infection
over time or with increased doses (Figures 7 and S2). We recommend
analyzing the infected resident peritoneal MVs between days 3 and 7
after injection, when the percentage of infected resident peritoneal
MVs is at its highest and inﬂammation is reduced. In some cases,
such as shRNA knockdown of targets, day 7 is preferred to allow
time for clearance of pre-existing protein, an approach we used
recently to knock down Map3k8 and Gata6 expression in vivo.18
In summary, the validation of speciﬁcity of lentivirus infection during
peritoneal cavity injection demonstrates its explicit targeting to tissue
resident peritoneal MVs. High frequency and intensity of EGFP was
recorded in those cells with little background infection in other cell
populations. A 100 mL dose of lentivirus ensured the best balance be-
tween the infection efﬁciency of target cells and an inﬂammatory
response. However, the optimal amount of lentivirus for injection is
strictly dependent on the quality of lentivirus stock obtained
following this protocol.We strongly recommend estimating the infec-
tivity of every lentivirus production in Jurkat T cells and scaling the
injection volume accordingly.
Timing
HEK293T Cell Transfection (3 Days)
 Day7: Thaw and passage HEK293T cells at least two times before
seeding for lentivirus productionar Therapy: Methods & Clinical Development Vol. 16 March 2020 27
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Figure 6. Infection Efficiency of the Resident peritoneal MV Subpopulation
(A) Percentage of total single cells and resident MVs viable 7 days after 100 mL AimV () or lentivirus i.p. injection. (B) Gating strategy showing four major populations of
peritoneal MVs that can be found in vivo: CD73+ Tim4+, CD73 Tim4+, CD73+ Tim4, and CD73 Tim4. (C) Percentage of EGFP+ andMFI of EGFP+ of each peritoneal MV
subpopulation 3 days after infection with 100 mL lentivirus in a total volume of 200 mL AimVmedium. (D) Percentage of EGFP+ cells in multiple organs 7 days after lentivirus i.p.
injection. mLN, mesenterial lymph node. (E) Gating strategy of peritoneal MVs and monocytes 3 days after lentivirus i.p. injection. (F) Percentage, MFI, and cell number
analysis of EGFP+ monocytes (Ly6Chi) and MV (Ly6C). Data are expressed as mean ± SEM.
www.moleculartherapy.org Day 0: Count and seed the cells
 Day 1: Transfection
 Day 3: Transfection efﬁciency check
Lentivirus Collection and Purification (1–2 Days)
 Day 1: Collection, spin, aliquot (if doing the optional second step,
add fresh medium to the infected HEK293T cells)
 Day 2 (Optional): Second collection
Lentivirus Infectivity (3 Days)
 Day 7: Thaw and passage Jurkat T cells at least two times before
infection
 Day 0: Counting and seeding Jurkat T cells and infection
 Day 3: Measurement of infection efﬁciency by ﬂow cytometryFigure 5. Resident Peritoneal Macrophage (peritoneal MV) Infection
(A) Gating strategy to define resident peritoneal MVs. Cells are first gated on singles, f
Control non-infected peritoneal lavage was used here, but the strategy is the same for in
peritoneal MVs isolated 3 days after in vivo infection with various amount of lentivirus (5
histogram (E) of Flow cytometry analysis of resident peritoneal MVs isolated 4 h, 3 days
200 mL AimV medium. (F) Gating strategy and representative pictures of Imagestream an
injected with 200 mL of neat AimV medium. Data are expressed as mean ± SEM.
MoleculIn Vivo peritoneal MV Infection and Cell Staining (3–7 Days)
Caution: mice welfare should be monitored daily for the duration of
the protocol.
 Day 0: i.p. injection
 Days 3–7: Collection of peritoneal cells and staining and analysis
Troubleshooting
Poor Lentivirus Titer
Poor lentivirus titer could be a result of several issues. Technical is-
sues include low viability of HEK293T cells, high conﬂuency of
HEK293T cells on the day of transfection, suboptimal HEK293T
cell transfection procedure (e.g., mixing of plasmids, suboptimal
plasmid quality, applying transfection reagent to the wall of the ﬂaskollowed by CD11b+. Resident peritoneal MVs are identified as Tim4+ F4/80+ cells.
fected lavages. Dot plots (B) and histogram (C) of Flow cytometry analysis of resident
0, 100, 150, or 200 mL in a total volume of 200 mL AimV medium). Dot plots (D) and
, 7 days, and 14 days after in vivo infection with 100 mL lentivirus in a total volume of
alysis of the lentivirus core antigen localization in peritoneal MVs. Control mice were
ar Therapy: Methods & Clinical Development Vol. 16 March 2020 29
AB
Figure 7. Impact of Lentivirus Infection on Peritoneal Inflammation
(A) Percentage of cells at various times (4 h, 3 days, 7 days, and 14 days) after i.p.
injection of 100 mL of lentivirus. (B) MFI of the EGFP+ cells 7 days after the injection of
100 mL of lentivirus. All lentivirus injections were performed with the same total
volume of 200 mL (completed by AimV medium). Control mice (”C”) received 200 mL
of neat AimV medium. Data are expressed as mean ± SEM.
Molecular Therapy: Methods & Clinical Developmentinstead of to the cells directly), and usage of a 0.22-mm ﬁlter rather
than a 0.45-mm ﬁlter to ﬁlter collected medium. Alternatively, the
infectivity of lentivirus preparation can be inﬂuenced by the gene
inserted in the transfer plasmid. If the gene of interest is very
long, it can possibly result in a lower rate of successful reverse tran-
scription and genome integration, resulting in a lower percentage of
gene expression.
It is important to note that the permeabilization of cells required
when staining for intracellular protein can affect some reporter pro-
teins. We repeatedly observed a strong decrease of EGFP intensity
when permeabilizing the cells. In this case, an anti-reporter protein
stain should be considered.30 Molecular Therapy: Methods & Clinical Development Vol. 16 MarchHigh Amount of Lentivirus Stock Required
If a high amount of lentivirus is required for experiments, we recom-
mend preparing an adequate number of ﬂasks for the production
(1  T175 ﬂask = max 1.5 mL of lentivirus preparation) and mixing
the ﬁnal collection from the same time point from all ﬂasks before ali-
quoting. This ensures reproducible results between the aliquots and
reduces the number of samples for titration. When making larger
stocks, prepare the plasmids mix (see 1.3 Transfection Using an Effec-
tene Kit) in 50 mL tubes rather than 15 mL to ensure good mixing.
Peritoneal Inflammation after Lentivirus Injection
As we demonstrated, a low level of inﬂammation can be observed in
the peritoneal cavity following lentivirus injection. If major or sus-
tained inﬂammation is observed, please review your protocol and
consider possible contamination when preparing lentivirus.
General Restriction to Further Analyses
Because of the nature of lentiviruses, their use should be reconsidered
when further analyses include antiviral response of peritoneal MVs.
VSV-G pseudotyped single round replication HIV-1, similar to the
construct employed in this protocol, was shown to induce some of
the IFN-stimulated genes (ISGs) in human MVs in the absence of
detectable type-I IFN.26 Although, we cannot exclude sensing of the
lentivirus and low level of antiviral response, our experiments did
not detect type I IFNs in the lentivirus-challenged peritoneal cavity.
Lentivirus Storage and Viability
To avoid multiple freeze-thaw cycles, lentivirus preparations should
be aliquoted straight after preparation and kept at80C.We recom-
mend freezing 100 mL of lentivirus per aliquot covering the optimal
injection volume (100 mL) plus possible aliquoting error (20 mL). If
injecting more than one mouse, we recommend combining lentivirus
aliquots prior to loading of the syringes. We found lentivirus to be
viable up to 6 months post preparation if stored correctly. Any longer
storage could potentially result in a reduced infection rate, and infec-
tivity of the virus should be tested again.
Safety Concerns when Using Lentivirus
Any procedures covering lentivirus work should be covered in stan-
dard operating procedures (SOPs) and risk assessments (RAs) pre-
pared by the laboratory safety ofﬁcer for each institute in accordance
with local and national guidelines. For recommendations regarding
safe lentivirus handling, please refer to Box 1.
Anticipated Results
Here, we describe a comprehensive protocol for producing pure lenti-
virus stocks for in vivo peritoneal MV gene modiﬁcation in mice. We
explain in detail the lentivirus productionmethod and subsequent steps
of lentivirus i.p. injection and data analysis. When followed correctly,
the protocol yields a total of 1.5 mL of high-quality lentivirus stock
per single preparation. Such volume is equivalent to a minimum of
twelve in vivo i.p. injections, allowing high-scale studies at reasonable
costs. This protocol is, to date, the only one combining rapidity, repro-
ductivity, and high speciﬁcity of murine peritoneal MV gene targeting.2020
www.moleculartherapy.orgAlthough we demonstrated the precise targeting of peritoneal MVs,
low and transient levels of inﬂammation can be detected in the peri-
toneal cavity following lentivirus injection, probably due to local
response to the viral presence.
This protocol is mostly recommended for short-term investigation
(up to 2 weeks after i.p. injection), as the disappearance of peritoneal
MVs 2 weeks post injection was recorded.
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